Myotonic Dystrophy clinical trials at UC Irvine

1 research study open to eligible people

Showing trials for

  • PK, and PD Study of PGN-EDODM1 in Participants with Myotonic Dystrophy Type 1

    open to eligible people ages 18-50

    The primary purpose of the study is to evaluate the safety and tolerability of single intravenous (IV) doses of PGN-EDODM1 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study consists of 2 periods: A Screening Period (up to 30 days) and a Treatment and Observation Period (16 weeks).

    Irvine, California and other locations